High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza.

Clinical and Vaccine Immunology : CVI
Kelvin K W ToKwok-Yung Yuen

Abstract

The importance of neutralizing antibody in protection against influenza virus is well established, but the role of the early antibody response during the initial stage of infection in affecting the severity of disease is unknown. The 2009 influenza pandemic provided a unique opportunity for study because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody responses of 52 patients with severe or mild disease, using sera collected at admission. A microneutralization (MN) assay was used to detect neutralizing antibody. We also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and nonneutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titers were not significantly different between the two groups (P = 0.764), the ELISA titer and ELISA/MN titer ratio were significantly higher for patients with severe disease than for those with mild disease (P = 0.004 and P = 0.011, respectively). This finding suggested that in patients with severe disease, a larger proportion of serum antibodies were antibodies with no detectable neutralizing activity. The antibody avidity was also significantl...Continue Reading

References

Jan 1, 1979·British Medical Bulletin·C W Potter, J S Oxford
Mar 29, 1969·Nature·J L Gerin, N G Anderson
Feb 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I ChaloupkaH Meier-Ewert
Sep 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Damian M CarragherTroy D Randall
Apr 16, 2009·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Bernhard Meier
Aug 13, 2009·Archives of Virology·Ingrid KrejnusováGustáv Russ
Sep 12, 2009·The New England Journal of Medicine·Kathy HancockJacqueline M Katz
Sep 29, 2009·Microbes and Infection·Christina EhrhardtStephan Ludwig
Oct 10, 2009·The New England Journal of Medicine·Steven A R WebbMichael Yung
Dec 2, 2009·Journal of Medical Virology·Kelvin K W ToKwok-Yung Yuen
Feb 9, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kelvin K W ToKwok-Yung Yuen
Mar 20, 2010·BMJ : British Medical Journal·Stephen E Lapinsky
Apr 27, 2010·Innate Immunity·Tesfaldet TecleKevan L Hartshorn
Jun 26, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan F N HungKwok-Yung Yuen
Jul 28, 2010·Experimental Biology and Medicine·Bojian ZhengKwok-Yung Yuen
Sep 30, 2010·Clinical and Vaccine Immunology : CVI·Sukathida Ubol, Scott B Halstead
Oct 5, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wei LiuWu-Chun Cao
Dec 7, 2010·Nature Medicine·Ana Clara MonsalvoFernando P Polack
Dec 21, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Karim El BakkouriXavier Saelens
Jan 7, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Janice K LouieUNKNOWN California Pandemic (H1N1) Working Group
Mar 2, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mark W LaMereDenise A Kaminski
Mar 23, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Elizabeth E Waffarn, Nicole Baumgarth
Jun 8, 2011·Immunology and Cell Biology·Garry W LynchJohn S Sullivan
Sep 9, 2011·Clinical and Vaccine Immunology : CVI·Anna J X ZhangKwok-Yung Yuen
Sep 21, 2011·The Journal of Infectious Diseases·Anuja MathewAlan L Rothman
Oct 15, 2011·The Journal of Infectious Diseases·Suzanne E OhmitArnold S Monto
Dec 20, 2011·Nature Immunology·Arturo Casadevall, Liise-Anne Pirofski

❮ Previous
Next ❯

Citations

Aug 24, 2013·The Lancet Infectious Diseases·Kelvin K W ToKwok-Yung Yuen
Aug 13, 2013·The Journal of Infectious Diseases·Shigui YangLanjuan Li
Aug 30, 2013·Science Translational Medicine·Surender KhuranaHana Golding
Jul 11, 2013·Clinical & Developmental Immunology·Andrew HiattKevin J Whaley
Aug 13, 2013·Clinical & Developmental Immunology·Giuseppe SauttoMassimo Clementi
Jan 23, 2014·Emerging Infectious Diseases·Li GuoJianwei Wang
May 3, 2014·Viruses·Han ZhangBao-Zhong Wang
Jun 10, 2014·The Journal of Clinical Investigation·Olivia BonduelleBehazine Combadiere
Jun 17, 2014·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·John Patrick HaranShan Lu
Jan 1, 2014·Vaccines·Claudia Maria TrombettaEmanuele Montomoli
Sep 10, 2014·Viruses·Yo Han Jang, Baik Lin Seong
Jul 22, 2014·Annals of the New York Academy of Sciences·Sarah Cobey
Apr 16, 2015·Human Vaccines & Immunotherapeutics·Kui XiangSun Maosheng
Jun 4, 2018·The Journal of Infectious Diseases·Hillary A VandervenUNKNOWN INSIGHT FLU005 Pilot Study Writing Group
Jun 13, 2014·Clinical and Vaccine Immunology : CVI·Jean-Louis ExclerStanley A Plotkin
Apr 12, 2019·Journal of Virology·Andrew K HastingsErol Fikrig
Jul 13, 2019·Proceedings of the National Academy of Sciences of the United States of America·Katie L WinarskiSurender Khurana
Jul 4, 2019·Scandinavian Journal of Immunology·Shahinul IslamKarl Albert Brokstad
Apr 23, 2016·Human Vaccines & Immunotherapeutics·Quentin CanelleRobbert van der Most

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.